Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) Short-Term Debt: ¥233 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688796 Biocytogen Pharmaceuticals (Beijing) Co Ltd SHSE:688796
53 GF Score
Price ¥134.13
GF Value ¥76.48
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Biocytogen Pharmaceuticals (Beijing) Co Short-Term Debt?

Biocytogen Pharmaceuticals (Beijing) Co SHSE:688796 -2.80% 53 Short-Term Debt is ¥233 Mil as of Jun. 2026. GuruFocus rates SHSE:688796 with a GF Score™ of 53/100 and a GF Value™ of ¥76.48 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Biocytogen Pharmaceuticals (Beijing) Co's Short-Term Debt for the quarter that ended in Jun. 2026 was ¥233 Mil.

Biocytogen Pharmaceuticals (Beijing) Co's quarterly Short-Term Debt increased from Jun. 2025 (¥215 Mil) to Dec. 2025 (¥562 Mil) but then declined from Dec. 2025 (¥562 Mil) to Jun. 2026 (¥233 Mil).

Biocytogen Pharmaceuticals (Beijing) Co's annual Short-Term Debt declined from Dec. 2023 (¥326 Mil) to Dec. 2024 (¥312 Mil) but then increased from Dec. 2024 (¥312 Mil) to Dec. 2025 (¥562 Mil).

Biocytogen Pharmaceuticals (Beijing) Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Biocytogen Pharmaceuticals (Beijing) Co Short-Term Debt Related Terms

Biocytogen Pharmaceuticals (Beijing) Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co Short-Term Debt Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 75.45 323.97 325.75 311.62 561.56

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Apr20 Dec21 Dec22 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only 344.59 311.62 214.63 561.56 232.54
SHSE:688796
53GF Score
Biocytogen Pharmaceuticals (Beijing) Co Ltd SHSE:688796
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥233 Mil mean?
Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) has a Short-Term Debt of ¥233 Mil as of Jun. 2026.
Is Biocytogen Pharmaceuticals (Beijing) Co's Short-Term Debt too high?
Biocytogen Pharmaceuticals (Beijing) Co's current Short-Term Debt is ¥233 Mil. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's Short-Term Debt compare to VRTX and REGN?
Biocytogen Pharmaceuticals (Beijing) Co's Short-Term Debt of ¥233 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Biocytogen Pharmaceuticals (Beijing) Co's current Short-Term Debt is ¥233 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥76.48, compared to a current price of ¥134.13 — trading 75.4% above its estimated fair value. The current Short-Term Debt is ¥233 Mil. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796), the current Short-Term Debt is ¥233 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) Overvalued in 2026?

Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued. The current stock price of ¥134.13 is trading 75.4% above its estimated GF Value™ of ¥76.48. GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.

Key valuation signals for SHSE:688796:

  • Short-Term Debt: ¥233 Mil
  • GF Value™: ¥76.48 vs. price of ¥134.13 (75.4% above fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the SHSE:688796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Other Exchanges 02315:Hong KongI54:Germany
Address 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
53GF Score

Get the complete analysis for SHSE:688796

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥134.13
Price
¥76.48
GF Value